Azbil BioVigilant (ABV) Announces Partnership with University of Tennessee (UT) Pharmacy College
News Apr 08, 2013
Azbil BioVigilant, Inc. announced that the University of Tennessee (UT) Pharmaceutical Sciences Department will utilize Azbil BioVigilant’s IMD-A® 300-series of rapid microbial monitoring systems in their state-of-the-art aseptic filling facility.
The University of Tennessee is a leading institution in training individuals in health sciences fields, and for the past 50 years has offered training in aseptic processing. “Our new manufacturing facility, now under construction, will provide an advanced training ground featuring cutting-edge technology such as Azbil BioVigilant’s IMD-A system capable of real-time, around-the-clock environmental monitoring,” said Professor Laura Thoma, Director of UT’s Plough Center for Sterile Drug Delivery. “This laser-based technique leverages naturally-occurring fluorescence to detect microbes, in contrast to the culturing method in widespread use developed over a century ago,” she added.
Aric Meares, CEO of Azbil BioVigilant, stated partnerships such as these signify enabling steps for the industry. “The FDA continues to encourage the adoption of new technologies that improve the sterile manufacturing process and reduce the contamination risk to medications. The pharmaceutical industry has made limited advancements in this area due, in part, to the lack of published data. Our partnership with the University of Tennessee will help to fill that information void,” he added.
The University aims to complete research on topics of wide interest to pharmaceutical drug makers such as the relevance and impact of paradigm-changing microbial detection sensitivity via intrinsic fluorescence, the impact of rapid access to information warning of a change of state within the drug-making environment, and the use of IMD-A systems as part of a larger parametric (or real-time) product release process.
Azbil BioVigilant’s IMD-A 300 and IMD-A 350 systems can detect immediately the presence of microbes in the pharmaceutical manufacturing process, and in doing so, greatly accelerate the quality assurance processes for drug batch release.
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Comments | 0 ADD COMMENT
3rd Annual Bioprocessing of Advanced Cellular Therapies
May 29 - May 30, 2018